ReviewLife (Basel, Switzerland)2023
The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Mitochondrial Long Non-Coding RNAs in Gynecological Cancers: Pathogenic Signaling Pathways and Therapeutic Opportunities.Current issues in molecular biology · 2026Review
- Does immunotherapy hold great promise in endometrial cancer care?Frontiers in immunology · 2026Review
- Current Unveiling Key Research Trends in Endometrial Cancer: A Comprehensive Topic Modeling Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Expression Characteristics and Prognostic Value of KLRG2 in Endometrial Cancer: A Comprehensive Analysis Based on Multi-Omics Data.Biomedicines · 2025Article
- Adaptive Target Volume and Dosimetry in Image-Guided Radiotherapy for Cervical Cancer.Journal of clinical medicine · 2025Article
- Knowledge, Attitudes, and Behaviors Regarding Sexually Transmitted Infections Among Romanian Medical Students: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- WOAENet: a whale optimization-guided ensemble deep learning with soft voting for uterine cancer diagnosis based on MRI images.Frontiers in artificial intelligence · 2025Article
- Global burden of polycystic ovary syndrome, uterine cancer and diabetes mellitus type 2 among women of childbearing age: trends in incidence, prevalence, mortality, and disability-adjusted life-years from 1990 to 2021.Frontiers in medicine · 2025Article
- Uterine Carcinosarcoma (UCS): A Literature Review and Survival Analysis from a Retrospective Cohort Study.Cancers · 2024Article
- Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer.medRxiv : the preprint server for health sciences · 2024Article
- The Immune Response of Cancer Cells in Breast and Gynecologic Neoplasms.International journal of molecular sciences · 2024Review
- Temporal Trends in Treatment and Outcomes of Endometrial Carcinoma in the United States, 2005-2020.Cancers · 2024Article
- Review
- Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.International journal of molecular sciences · 2024Review
- Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer affects the uterus and is becoming increasingly common and deadly. Although surgery and adjuvant pelvic radiotherapy can often cure the disease when it is contained in the uterus, patients with metastatic or recurrent disease have limited response rates to chemotherapy, targeted agents, and hormonal therapy. To address this unmet clinical need, innovative treatment strategies are needed, and a growing focus on the immunomodulation of the tumor microenvironment has arisen. Current data suggest that active and/or passive immunotherapy may be promising for the treatment of endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.